Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

First Data From Health Economic Model Show Managing Hypoglycaemia Could Cost NHS £363.6 Million Per Year


News provided by

Novo Nordisk

16 Sep, 2014, 09:59 GMT

Share this article

Share toX

Share this article

Share toX

50TH EASD ANNUAL MEETING, VIENNA, September 16, 2014 /PRNewswire/ --

UK medical media only

Economic burden of hypoglycaemia could even be higher due to significant under-reporting, an additional study shows   

New figures released today show the cost of managing hypoglycaemia in the UK could be £363.6 million per year (£235.6 million for severe episodes and £128 million for non-severe). The economic burden of hypoglycaemia, calculated using the Local Impact of Hypoglycaemia Tool (LIHT), was presented today at the European Association for the Study of Diabetes (EASD) 50th Annual Meeting. The LIHT model estimates that hypoglycaemic episodes in adults that require NHS resources could cost up to £2,195, and this could increase substantially with an extended stay in hospital[1].

Existing figures on the rates of hypoglycaemia among people with diabetes have already demonstrated it to be one of the most common short-term complications of this complex condition. Those with type 1 diabetes have been shown to experience approximately two non-severe episodes per week, and insulin-treated patients with type 2 diabetes experience approximately one non-severe episode every two weeks[2]. Severe hypoglycaemia can require emergency assistance - and research has shown that people with type 1 diabetes may experience on average 3.2 severe episodes per year, with those with type 2 diabetes experiencing approximately 0.7 severe episodes per year[3].

LIHT estimates the economic impact of severe and non-severe hypoglycaemic episodes in national and local populations. On a local health economy level, assuming a hypothetical population of 100,000, LIHT estimates the total cost of managing hypoglycaemic episodes to be £543,493 per year (£352,163 for severe episodes, £191,330 for non-severe episodes). With a hypothetical reduction in hypoglycaemia rates of 25% (totalling 364 severe episodes and 3,759 non-severe episodes) the LIHT shows a potential cost saving of £135,873 per 100,000 people, equating to £90.9 million for the UK as a whole[1].

Witesh Parekh, Health Economist at Novo Nordisk and Lead Developer of LIHT, commented: "LIHT highlights the economic burden of hypoglycaemia against any given population, but more importantly it can demonstrate the savings that could be made by reducing incidence of hypoglycaemia. Novo Nordisk has developed the LIHT to help assist healthcare professionals and NHS budget holders with decision making for the overall management of hypoglycaemia. In particular, it offers an opportunity to offset costs of new insulin treatments and patient education programmes with costs of hypoglycaemic episodes, thus improving patient care."

The economic burden of hypoglycaemia is likely to be underestimated. Incidence of hypoglycaemia is significantly under-reported in insulin-treated patients with diabetes (type 1 and type 2), data from the largest ever global study on hypoglycaemia have shown[4]. The results of the Hypoglycaemia Assessment Tool (HAT) study reveal the importance of identifying the impact of hypoglycaemia and taking action to manage this common diabetes complication.

The HAT study, also presented today at the EASD 50th Annual Meeting, was designed to determine the extent of self-reported hypoglycaemia experienced in a global population of patients with insulin-treated diabetes, using self-assessment questionnaires and patient diaries. The findings showed an increase in incidence of overall hypoglycaemia in the four-week evaluation period after the study compared to the four-week evaluation prior to the study*[4]:

  • 47% increase in the number of events per patient year in type 1 diabetes
  • 20% increase in the number of events per patient year in type 2 diabetes

The increased incidence of overall hypoglycaemia in the reporting period after the study suggests significant under-reporting from patients for all types of hypoglycaemia. Rates of overall, nocturnal and severe hypoglycaemia were also higher than previously demonstrated in other studies.

Professor Kamlesh Khunti, Professor of Primary Care Diabetes & Vascular Medicine, University of Leicester, noted: "It is clear from the results of this study that people with diabetes often do not recognise and report episodes of hypoglycaemia. As healthcare professionals, we should be actively educating patients to ensure they fully understand what a hypoglycaemic event is, how to accurately record any incidences and, importantly, report them so that we are able to discuss management strategies - which may include tailoring treatment regimens according to individual patient need."

*Hypoglycaemic events were reported by patients based on self-reported symptoms and/or measured low blood sugar levels (≤70 mg/dl (3.9 mmol/l)). Severe hypoglycaemia was defined as events requiring 3rd party assistance.

Notes to the editor   

Hypoglycaemia   

  • Hypoglycaemia occurs when blood glucose levels fall to lower than normal levels (4mmol/L), causing unpleasant symptoms and can be very dangerous[5],[6].
  • Hypoglycaemic events can range from non-severe (e.g. a pounding heart, trembling, hunger, difficulty concentrating and blurred vision) to severe (e.g. unconsciousness, coma or death); people who experience severe events will need help from another person to manage their symptoms and may require hospital treatment[7].
  • Research shows that fears and concerns about hypoglycaemia can interfere with achieving optimal glycaemic control in people with diabetes using insulin[8].
  • Hypoglycaemia that occurs during the night is of particular concern for people with insulin-treated diabetes, as it is often unpredictable and difficult to detect[9].

Hypoglycaemia Assessment Tool (HAT) study     

HAT is a non-interventional, multicentre, six-month retrospective, one-month prospective study of hypoglycaemic events across 24 countries using self-assessment questionnaires and patients diaries (for 28 days) in people aged 18 years and older with type 1 or type 2 diabetes using insulin for more than 12 months.

Local Impact of Hypoglycaemia Tool (LIHT)   

The LIHT is an iPad application that healthcare professionals can use with a Novo Nordisk Diabetes Outcomes Director. Healthcare professionals are provided with a summary report highlighting the key findings and a bespoke slide-set.

Alongside healthcare professionals, Novo Nordisk Diabetes Outcomes Directors will select a region or population of interest and, based on the epidemiology of diabetes, the model estimates the number of insulin-treated adults with type 1 and type 2 diabetes in that region.

Using hypoglycaemia rates from the UK Hypoglycaemia Study Group (UKHSG) observational study and the cost of hypoglycaemic episodes - which has been estimated through healthcare resource unit costs and utilisation figures from various sources including Personal Social Services Research Unit, NHS Tariffs, MIMS, NHS data, NICE guidelines and other published data - the annual cost of severe and non-severe hypoglycaemic episodes in that population is estimated.

The research was conducted and model developed by Novo Nordisk in collaboration with Abacus International and with expert clinical input from Dr Marc Evans.

About Novo Nordisk   

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.co.uk.

Further information   

LIHT is available to those wishing to assess data for their locality via a Novo Nordisk Diabetes Outcomes Director. To contact Novo Nordisk, please call 01293 613555 or email wpa@novonordisk.com.

References:   

1. Parekh WA, et al. The 'Local Impact of Hypoglycaemia Tool (LIHT)' for estimating the economic impact of hypoglycaemic episodes in national, local and user-defined populations. Presented at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), Vienna, Austria; 15-19 September 2014.

2. Ostenson C, et al. Research: Complications Self-reported non-severe hypoglycaemic events in Europe. Diabet Med. 2014;31(1):92-101.

3. U. K. Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes:

effects of treatment modalities and their duration. Diabetologia. 2007 Jun;50(6):1140-7.

4. Khunti K, et al. Self-reported hypoglycaemia: A global study of 24 countries with 27,585 insulin-treated patients with diabetes. The HAT study. Presented at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), Vienna, Austria; 15-19 September 2014.

5. American Diabetes Association. Common Terms: Hypoglycemia. Available at: http://www.diabetes.org/diabetes-basics/common-terms/common-terms-f-k.html. Accessed July 2014.

6. American Diabetes Association Working Group on Hypoglycemia. Defining and reporting hypoglycemia in diabetes. Diabetes Care 2005;28:1245-9.

7. Cefalu CA, et al. Controlling hypoglycemia in type 2 diabetes: Which agent for which patient? J Fam Pract. 2005;54:855-62.

8. Hex N, et al. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855-62.

9. Allen KV, et al. Nocturnal hypoglycaemia: clinical manifestations and therapeutic strategies toward prevention. Endocr Pract. 2003;9:530-43.

Media:
Liz Skrbkova
+44(0)-7919-590-622
lzsk@novonordisk.com

Novo Nordisk Ltd
Corporate Communications
Telephone: +44 1293 613555

Date of preparation: September 2014
UK/CC/0914/0082

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.